Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study by Satoshi Ida et al.
Ida et al. Cardiovasc Diabetol  (2016) 15:153 
DOI 10.1186/s12933-016-0468-4
ORIGINAL INVESTIGATION
Effect of trelagliptin on vascular 
endothelial functions and serum adiponectin 
level in patients with type 2 diabetes: a 
preliminary single-arm prospective pilot study
Satoshi Ida1*, Kazuya Murata1, Katunori Betou2, Chiaki Kobayashi2, Yuki Ishihara1, Kanako Imataka1, 
Akihiro Uchida1, Kou Monguchi1, Ryutaro Kaneko1, Ryoko Fujiwara1 and Hiroka Takahashi1
Abstract 
Background: Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long 
half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The 
objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients 
with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylargi-
nine (ADMA) as evaluation indicators.
Methods: This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM 
patients aged 20–74 years, who visited our outpatient department. The patients were treated with trelagliptin, and 
their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to deter-
mine the changes during the study period.
Results: A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin 
treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) 
and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment 
resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-
treatment, P < 0.002).
Conclusions: In this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it 
was believed that trelagliptin treatment may increase serum adiponectin level.
Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311)
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Background
The incidences of type 2 diabetes mellitus (DM) have 
been increasing during recent years and are associated 
with increasing incidences of cardiovascular diseases, 
which comprise a serious potential outcome [1]. There-
fore, a key objective of type 2 DM management is the 
prevention of cardiovascular diseases. It has been sug-
gested that the onset of cardiovascular diseases is associ-
ated with decreased arterial dilatation [2]. Flow-mediated 
dilatation (FMD) is extensively used to evaluate arterial 
dilatation [3]. Decreased arterial dilatation is triggered 
by a decline in nitric oxide (NO) production [4]. Some 
researchers have reported a decrease in NO production 
or its activity in DM patients [5].
In recent years, antidiabetic drugs with new mecha-
nisms of action have become available. Of these, incretin 
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preparations [e.g., dipeptidyl peptidase-4 (DPP-4) inhibi-
tors and glucagon-like peptide-1 (GLP-1) analogs] 
improve FMD; this improvement is mediated by NO pro-
duction or activation as well as effects such as the promo-
tion of insulin secretion and inhibition of glucagon [6].
Trelagliptin is now considered as an oral DPP-4 inhibi-
tor administered once per week and characterized by a 
long half-life in the blood. However, the effects of trela-
gliptin on vascular endothelial functions have not been 
clarified to date. The objective of the present study was 
to examine the effects of trelagliptin treatment on vascu-




This study was an open-label prospective single-arm trial. 
At baseline and 12 weeks following the initial treatment 
with trelagliptin (50–100  mg once per week), we evalu-
ated the FMD, adiponectin level, asymmetric dimethy-
larginine (ADMA) level, mean carotid intima media 
thickness (CIMT), mean brachial-ankle pulse wave veloc-
ity (baPWV), fasting blood glucose level, hemoglobin 
A1c (HbA1c) level, serum lipid level, body weight, and 
body mass index (BMI).
Subjects and setting
The subjects of this study were type 2 DM patients 
aged 20–74  years, who visited our outpatient depart-
ment between July 2015 and June 2016. Eligibil-
ity criteria were patients with poor glycemic control 
(6.5%  ≤  HbA1c  <  10% or 110  mg/dL  ≤  fasting blood 
glucose < 250 mg/dL) despite ≥8 weeks of diet and exer-
cise therapies and patients with poor glycemic control 
despite treatment with oral antidiabetic drugs (excluding 
pioglitazone, which may have potent effects on vascu-
lar endothelial functions [7]). If patients used oral anti-
diabetic drugs before trelagliptin treatment, they were 
enrolled on the condition that treatment with such drugs 
had been initiated at least 8  weeks prior to the current 
treatment. Exclusion criteria were patients with a his-
tory of type 1 DM, insulin dependence, acute diabetic 
complications (e.g., diabetic ketoacidosis), secondary 
DM, pancreatitis, severe infections, alcoholism, severe 
mental disorders, and malignant tumors. Furthermore, 
patients with a fasting blood glucose level of ≥250  mg/
dL, being treated with drugs that may affect the fasting 
blood glucose level (e.g., glucocorticoids), with hepatic 
dysfunction [with aspartate aminotransaminase (AST) 
and alanine aminotransferase (ALT) levels exceeding the 
upper limits of the institution’s baselines], with systolic 
blood pressure ≥160 mmHg, who had developed severe 
vascular diseases that required hospitalization within 
previous 6  months (e.g., stroke and myocardial infarc-
tion), who were or may be pregnant, with serum creati-
nine level of  ≥1.5  mg/dL or creatinine clearance (Ccr) 
level of <30 mL/min, and who were deemed ineligible to 
participate by their physicians were excluded from the 
study [8–10].
Treatment
Patients were treated with trelagliptin after a dose adjust-
ment based on the renal function (i.e., when the serum 
creatinine level was  ≥1.4  mg/dL in men and  ≥1.2  mg/
dL in women or Ccr level was  <50  mL/min, the dose 
was reduced to 50 mg per week). When patients had no 
renal dysfunction, they were treated with a typical dose 
of 100  mg/week. It was decided to treat patients who 
discontinued the treatment during the study period 
(12 weeks) as dropouts. Even after the initiation of treat-
ment with trelagliptin, the patients were encouraged to 
continue the diet and exercise therapies. In case patients 
concomitantly used oral antidiabetic drugs that were not 
approved by their physicians or reduced or increased the 
dose of or discontinued the study drug, they were treated 
as dropouts.
When the HbA1c level was ≥8% even at ≥8 weeks after 
the initiation of trelagliptin treatment, it was decided 
that the following measures would be taken at the physi-
cians’ discretion: (1) in case of trelagliptin monotherapy, 
addition and gradual increase of another oral antidia-
betic drug and (2) in case of concomitant treatment with 
trelagliptin and another oral diabetic drug, the latter 
would be gradually increased [11]. When two or more 
hypoglycemic events were observed after the initiation 
of trelagliptin treatment, it was decided to taper the dose 
of the antidiabetic drug other than trelagliptin (oral sul-
fonylurea drug, if any) at the physician’s discretion. In 
case patients developed hypoglycemia, it was decided 
to have them orally ingest glucose and check their blood 
glucose levels every 15 min until their hypoglycemic con-
ditions disappeared. Hypoglycemia was defined as per-
sisting hypoglycemic symptoms that improved by glucose 
uptake, glucagon treatment, or dietary intake and a glu-
cose level of <50 mg/dL measured by self-monitoring the 
level or a blood test upon hospital arrival, regardless of 
the presence or absence of hypoglycemic symptoms [12].
Outcomes
The primary outcome was change in FMD at baseline 
and 12 weeks after the initial trelagliptin treatment. The 
secondary outcome was the change between baseline and 
12  weeks after trelagliptin treatment in the adiponectin 
level, ADMA level, mean CIMT, mean baPWV, fasting 
blood glucose level, HbA1c level, serum lipid level, and 
BMI.
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Flow‑mediated dilatation
FMD was evaluated following the previously published 
study guidelines [13]. It was decided to ask the subjects 
to control their smoking, dietary intake, caffeine-contain-
ing fluid intake, and the intake of drugs with antioxidant 
action (e.g., vitamin C or vitamin E preparations) for 12 h 
before performing FMD. If the subjects were on regular 
oral medications, they would not take such medications 
on the day of FMD measurement that was performed 
from 9 to 11 am. The subjects would rest in a supine posi-
tion for 15  min in a room maintained at 25  °C prior to 
the measurement. After inflating the blood pressure cuff 
wound around the right forearm to 50 mmHg above the 
systolic blood pressure for 5  min, the cuff was deflated 
to measure any changes in the right upper arm artery 
diameter. We measured the maximum diameter of the 
brachial artery, which dilated with increased blood flow 
within 2 min after the cuff release and expressed its ratio 
to the baseline artery diameter in percentage as FMD. 
The echocardiographic system and the probe used were 
the IE33 (Philips, Netherlands) and the L11-3 (Philips, 
Netherlands), respectively.
Carotid intima media thickness and brachial‑ankle pulse 
wave velocity
CIMT was measured with the patient in a supine posi-
tion with the neck extended after 15  min of rest. The 
measurement was performed at sites 10  mm proximal 
to the arch of the common carotid artery using bilat-
eral long-axis tomographic images. The mean CIMT 
was calculated as the mean value of the bilateral CIMT 
measurements. The value was expressed in millimeters 
[14]. The abovementioned echocardiographic system and 
probe were used for measurements. The measurement 
of baPWV was performed based on the PWV measured 
from volume pulse waves of the blood pressure cuffs 
wound around the upper arms and ankles using a blood 
pressure pulse wave measuring system (BP-203RPEIII, 
Omron Colin Co., Ltd., Japan). Measurements were per-
formed after the patient rested in the supine position 
for 5  min. PWV is an index of pressure waves ejected 
from the heart to the aorta and recorded as pulse waves 
between two points of a vessel. This index is obtained by 
dividing the distance by the time difference between the 
two points and expressed as a unit of speed (cm/min). 
The mean baPWV was obtained as a mean value of the 
bilateral measurements [15].
Measurement of other variables
Other variables that were recorded comprised age, 
sex, body weight, body mass index (BMI), smoking sta-
tus, alcohol consumption, DM duration, fasting blood 
glucose level, serum C-peptide level, immunoreactive 
insulin (IRI) level, homeostasis model assessment 
(HOMA) index, β-cell function, HbA1c level, estimated 
glomerular filtration rate (eGFR), estimated daily uri-
nary trace albumin amount, systolic blood pressure, 
diastolic blood pressure, low-density lipoprotein choles-
terol (LDLC) level, high-density lipoprotein cholesterol 
(HDLC) level, triglyceride (TG) level, presence/absence 
of diabetic retinopathy, presence/absence of diabetic 
neuropathy, presence/absence of nephropathy, and pres-
ence/absence of cardiovascular diseases. The use of oral 
antidiabetic drugs before trelagliptin treatment was also 
recorded. BMI was calculated using the equation: body 
weight (kg)/height (m2). The question about smoking 
status was “Do you currently smoke habitually?” and 
options for its answer were Yes and No. The question 
regarding the alcohol consumption habit was “Do you 
regularly consume liquor (sake, beer, shochu, plum wine, 
etc.)?” and options for its answer were Yes and No. Blood 
sample data were prepared from collected venous blood. 
The blood IRI was measured using an immunoradiomet-
ric assay. In addition, the HOMA index was calculated 
using the following formula: fasting blood glucose [mg/
dL] ×  fasting IRI [µU/mL]/405. The β-cell function was 
calculated using the following formula: 360 × fasting IRI 
(µU/mL)/fasting blood glucose (mg/dL) − 63 [16].
The serum lipids were determined using the standard 
enzymatic methods. We decided to measure and record 
the plasma glucose concentration using the glucose oxi-
dase method, and the HbA1c levels using high-perfor-
mance liquid chromatography based on the National 
Glycohemoglobin Standardization Program. The eGFR 
(mL/min/1.73  m2) was calculated using the following 
formula advocated by the Japanese Society of Nephrol-
ogy [17]: eGFRcre = 194 × Cre−1.094 × age−0.287 (×0.739 
for females). Traces of albumin in urine were measured 
using the turbidimetric method, and the estimated daily 
urinary albumin was measured by calculating the albu-
min–creatinine ratio (ACR) using the following formula: 
urinary trace albumin (mg/L)/urinary creatinine (mg/
dL) × 100. The unit used was mg/gCr. Systolic and dias-
tolic blood pressures were measured in a fasting state in 
the outpatient department and recorded as mmHg. The 
presence or absence of diabetic retinopathy was deter-
mined based on diagnoses by ophthalmologists. Moreo-
ver, the presence or absence of diabetic neuropathy was 
determined regardless of diagnosis of any of the following 
conditions: decreased Achilles tendon reflex, decreased 
vibratory sense in the lateral malleolus, and abnormal 
nerve conduction test results. The presence or absence 
of diabetic nephropathy was determined regardless of 
the diagnosis of nephropathy stage 2 or more advanced 
stages (ACR ≥  30  mg/gCr). The presence or absence of 
cardiovascular disease was determined regardless of 
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the patient currently suffering from or with a history of 
ischemic heart disease (e.g., angina pectoris, stroke, or 
arteriosclerosis obliterans). Adiponectin was measured 
using the latex agglutination method (LSI Medience Cor-
poration, Japan) and ADMA using the high-performance 
liquid chromatography method (SRL, Inc., Japan).
Safety
In this study, all potential adverse events were recorded 
as they occurred after the initiation of trelagliptin treat-
ment. When such events were suspected to have causal 
relationships with trelagliptin treatment and the treat-
ment was discontinued, the patients were considered to 
be dropouts.
Statistical analysis
The population for analysis comprised subjects who 
could be followed up to 12  weeks after the initiation of 
treatment, excluding the dropouts. In addition to the 
patient backgrounds, the following endpoints were 
evaluated at baseline and 12  weeks after the trelaglip-
tin treatment: FMD, adiponectin, ADMA, mean CIMT, 
mean baPWV, body weight, BMI, fasting blood glucose, 
HbA1c, eGFR, ACR, blood pressure, serum lipid, IRI, 
HOMA index, and β-cell function. For statistical analysis, 
Student’s t test or the Wilcoxon rank sum test was used. 
Furthermore, Pearson’s correlation analysis was used to 
examine the correlation between change in FMD and 
that in adiponectin level, ADMA level, HbA1c level, BMI, 
HOMA index, and β-cell function. The analysis was per-
formed using Stata version 12.0 (StataCorp LP, College 
Station, TX, USA), with a significance level (two-sided) 
of P < 0.05. This study was conducted after the acquisi-
tion of written informed consent from the participating 
patients and upon the approval by the ethics committee 
of Ise Red Cross Hospital physicians. This study was reg-
istered with the UMIN Clinical Trials Registry System 
(Trial ID UMIN000018311).
Results
A total of 30 patients who met the eligibility criteria 
were enrolled in this study. Of these, three patients were 
excluded as they discontinued oral drugs after the initia-
tion of treatment. The remaining 27 patients were treated 
as the population for analysis in this study. Patient back-
grounds at baseline are presented in Table 1. The mean 
age was 61.4 ± 10.8 years, and men represented 19 indi-
viduals of the population (70.3%). The duration of DM 
was 8.8  ±  7.6  years, BMI was 24.6  ±  3.2  kg/m2, and 
the HbA1c level was 7.4 ±  1.0%. The glomerular filtra-
tion rate was adequately maintained, with an eGFR of 
82.7  ±  21.1  mL/min/1.73  m2. An investigation of the 
antidiabetic drugs used before trelagliptin treatment 
demonstrated that the biguanides were most commonly 
used (16 patients), followed by sulfonylureas (8 patients).
Table  2 shows changes in each parameter at baseline 
and 12  weeks after trelagliptin treatment. Trelaglip-
tin treatment showed no significant changes in FMD 
(2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, 
P  =  0.785) and ADMA (0.41  ±  0.0  µg/mL at baseline 
vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trela-
gliptin treatment resulted in a significant increase of 
serum adiponectin level (7.72  ±  6.9  µg/mL at baseline 
vs. 8.82 ± 8.3 µg/mL at post-treatment, P = 0.002). Fast-
ing plasma glucose levels were significantly (P =  0.033) 
decreased, whereas HbA1c, BMI, and blood pressure 
did not significantly change. LDLC was significantly 
(P =  0.001) decreased, whereas HDLC and TG did not 
Table 1 Characteristics of patients included in the study
SD standard deviation, BMI body mass index, eGFR estimated glomerular 
filtration rate, ACR albumin creatinine ratio, HbA1c hemoglobin A1c, LDLC 
low-density lipoprotein cholesterol, HDLC high-density lipoprotein cholesterol, 
TG triglyceride, cardiovascular diseases comprise angina pectoris, myocardial 
infarction, stroke, and arteriosclerosis obliterans; SGLT2 sodium glucose 
cotransporter 2
* There is a case of duplicates
Age (years), mean (SD) 61.4 (10.8)
Male/Women (n) 19/8
BMI (kg/m²), mean (SD) 24.6 (3.2)
Body weight (kg), mean (SD) 64.9 (8.9)
HbA1c (%), mean (SD) 7.4 (1.0)
Fasting plasma glucose levels (mg/dL), mean (SD) 145.8 (35.9)
Duration of diabetes (years), mean (SD) 8.8 (7.6)
Alcohol consumption, % 36.0
Smoking, % 44.0
eGFR (mL/min/1.73 m2), mean (SD) 82.7 (21.1)
ACR (mg/gCr), mean (SD) 34.1 (54.6)
Systolic blood pressure (mmHg), mean (SD) 129.8 (8.0)
Diastolic blood pressure (mmHg), mean (SD) 79.7 (7.3)
LDLC(mg/dL), mean (SD) 120.5 (31.4)
HDLC (mg/dL) mean (SD) 53.2 (14.0)




Cardiovascular diseases, % 3.7
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significantly change. Mean ba-PWV was significantly 
(P = 0.045) decreased, whereas mean CIMT did not sig-
nificantly change. IRI, HOMA index, and β-cell function 
did not significantly change.
Correlations between change in FMD and various 
parameters are presented in Fig. 1. Pearson’s correlation 
coefficient between change in FMD and that in the adi-
ponectin level was 0.230 (P = 0.267) and in the ADMA 
level was 0.051 (P = 0.815) and that between change in 
FMD and that in HbA1c was −0.553 (P  =  0.004). No 
significant correlation was observed between change in 
FMD and that in BMI, HOMA index, and β-cell function.
Discussion
Trelagliptin treatment showed no significant changes 
in FMD and ADMA. On the other hand, trelagliptin 
treatment resulted in a significant increase of serum 
adiponectin level. Improvements in vascular endothe-
lial function with DPP-4 inhibitor treatment have been 
reported in previous studies [8, 9]. Some researchers 
have reported that DPP-4 inhibitor treatment caused 
blood GLP-1 levels to increase, thereby improving post-
prandial vascular endothelium function [18, 19], and 
others have reported the likelihood of GLP-1 recep-
tors existing in the vascular endothelium [20, 21]. Such 
reports have suggested the GLP-1 receptor-mediated 
direct improvement of vascular endothelial function. 
As we did not evaluate GLP-1 level and its influence on 
GLP-1 receptor in this study, we cannot mention these 
effects. On the other hand, although there was no signifi-
cant decrease in HbA1c level after trelagliptin treatment 
in this study, a significant correlation between decrease 
in HbA1c level and increase in FMD. It was believed that 
vascular endothelial function improvement as a result of 
blood glucose level improvement may be possible. The 
fact that we did not observe any statistically significant 
differences in FMD reductions as a result of trelagliptin 
administration in this study may have been due to a lack 
of statistical power resulting from the small sample size. 
Further investigation with a larger sample size needs to 
be conducted in the future. Furthermore, in this study, 
the value of FMD was low. The subjects in this study had 
a long history of diabetes and the ratio of smoking was 
relatively high compared with that in the precedent study 
[8, 9]. We believe that a long history of diabetes and lack 
of instructions pertaining to smoking cessation resulted 
in a low FMD [22, 23].
Adiponectin, secreted primarily by adipose tissue, 
is known to have multifaceted effects, such as anti-
inflammatory, antiarteriosclerotic, and antidiabetic 
activities [24, 25]. Adiponectin also increases the pro-
duction of NO, a factor with vasodilating effects [26, 
27]. Trelagliptin treatment in this study exhibited a sig-
nificant increase in adiponectin, but a weak correlation 
between change in FMD and that in the adiponectin 
level. There have been reports on increased adiponectin 
levels after treatment with vildagliptin or sitagliptin or 
on the potential vascular endothelial function improve-
ment mediated by increased adiponectin levels [8, 28, 
29]. The present study was unable to clarify the mecha-
nism of how trelagliptin treatment influences adiponec-
tin levels. Other studies on the effects of vildagliptin or 
sitagliptin on adiponectin levels [11, 30] have reported 
that decrease in direct or indirect oxidative stress [31] or 
decrease in visceral fat may be involved in the mecha-
nism of increase in adiponectin levels. As we did not 
evaluate oxidative stress or visceral fat in the present 
study, we cannot allude to this possibility via these 
mechanisms. On the other hand, one study reported 
that adiponectin levels did not significantly change after 
dipeptidyl peptidase-4 (DPP4) inhibitor treatment [32]. 
Further studies in the future are warranted to arrive at 
Table 2 Changes in  various parameters between  baseline 
and 12 weeks after trelagliptin therapy
SD standard deviation, FMD flow-mediated dilatation, ADMA asymmetric 
dimethyl arginine, BMI body mass index, eGFR estimated glomerular filtration 
rate, ACR albumin creatinine ratio, HbA1c hemoglobin A1c, LDLC low-density 
lipoprotein cholesterol, HDLC high-density lipoprotein cholesterol, TG 
triglyceride, IRI immunoreactive insulin, HOMA homeostasis model assessment, 
CIMT carotid intima media thickness, ba-PWV brachial ankle pulse wave velocity
Baseline After 12 weeks P value
FMD (%), mean (SD) 2.42 (2.7) 2.66 (3.8) 0.785
Adiponectin (μg/mL), mean 
(SD)
7.72 (6.9) 8.82 (8.3) 0.002
ADMA (μM/L), mean (SD) 0.41 (0.0) 0.40 (0.0) 0.402
BMI (kg/m2), mean (SD) 24.6 (3.2) 24.4 (3.0) 0.219
Body weight (kg), mean (SD) 64.9 (8.9) 64.5 (9.5) 0.266
HbA1c (%), mean (SD) 7.5 (1.0) 7.1 (0.9) 0.051
Fasting plasma glucose,  
mean (SD)
145.8 (35.9) 129.1 (36.4) 0.033
IRI (μU/mL), mean (SD) 14.3 (10.1) 14.5 (10.6) 0.913
HOMA index, mean (SD) 5.0 (4.0) 4.5 (4.2) 0.469
β-cell function, mean (SD) 69.0 (48.7) 88.3 (74.3) 0.193
eGFR (mL/min/1.73 m2),  
mean (SD)
82.7 (21.1) 79.8 (22.3) 0.062
ACR (mg/gCr), mean (SD) 39.7 (62.3) 34.7 (53.6) 0.244
Systolic blood pressure 
(mmHg), mean (SD)
129.8 (8.0) 129.9 (9.6) 0.945
Diastolic blood pressure 
(mmHg), mean (SD)
79.7 (7.3) 77.6 (8.8) 0.240
LDLC (mg/dL), mean (SD) 120.5 (31.4) 110.4 (28.7) 0.001
HDLC (mg/dL) mean (SD) 53.2 (14.0) 52.9 (12.9) 0.745
TG (mg/dL), mean (SD) 134.3 (49.4) 132.6 (54.5) 0.871
Mean CIMT (mm), mean (SD) 1.76 (1.3) 1.42 (0.5) 0.227
Mean ba-PWV (cm/s),  
mean (SD)
1633 (244.1) 1569 (217.1) 0.045
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the conclusion of whether increase in adiponectin levels 
is a class or drug effect.
ADMA is a naturally occurring methylarginine deriva-
tive and an endogenous inhibitor of nitric oxide synthase, 
which plays the most important role in the control of the 
vascular endothelial functions [33]. Therefore, increased 
ADMA levels impair the NO production required for 
vasodilation, resulting in decreased vasodilation. Ele-
vated ADMA levels are known as a predictive marker 
for the occurrence of cardiovascular diseases [34], and 
it is also known that DM patients have high ADMA lev-
els [35]. In previous studies, researchers have reported 
that saxagliptin treatment increased NO levels in the 
vascular endothelium in animal experiments [36]. In 
Fig. 1 Univariate correlations between the changes of %FMD and those of adiponectin, ADMA, HbA1c, BMI, HOMA index, and β-cell function 
between baseline and after 12 weeks of trelagliptin therapy
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addition, others have reported that vildagliptin treatment 
decreased ADMA levels [37]. Although the mechanistic 
details remain unknown, it is likely that DPP-4 inhibitor 
treatment improves the vascular endothelial functions 
by decreasing the ADMA levels, which in turn increases 
the NO levels. After trelagliptin treatment in this study, 
ADMA levels exhibited no significant changes, and a 
weak inverse correlation was observed between the 
change in FMD and that in the ADMA level. An inverse 
correlation between the ADMA level and FMD regarding 
vascular endothelial functions was reported in a previous 
study [38]. The lack of a statistically significant difference 
in ADMA decreases after trelagliptin administration may 
have been due to the sample size being too small. There-
fore, this issue needs to be investigated again in the future 
with a larger sample size.
Although LDL levels significantly decreased after trela-
gliptin treatment in this study, HDL and TG levels and 
blood pressure did not considerably change. Previous 
studies have reported decreased LDL, increased HDLC, 
and decreased TG levels and improved blood pressure 
after alogliptin or sitagliptin treatment [39–41]. Rea-
sons for some of the results obtained in this study being 
different from those of the previous studies include the 
enrollment of subjects for whom antihypertensive drugs 
or lipid-lowering drugs were administered and the likeli-
hood of the power being too weak because of the small 
population of patients. In this study, body weight and 
BMI did not considerably change after trelagliptin treat-
ment. Body weight reduction at 12  months after sitag-
liptin or vildagliptin treatment have been previously 
reported [30, 42]. Because the trial period was 3 months, 
we believe that in the future, it will be necessary to evalu-
ate the long-term effects of this drug on body weight and 
BMI. Decrease tendency of HOMA index scores and 
increase tendency of β-cell function were also observed 
in this study. These results require careful interpreta-
tion because the fasting blood glucose level at base-
line being  ≥140  mg/dL meant that HOMA index and 
β-cell function results may not be completely reliable 
[16]. In this study, a statistically significant decrease was 
observed for mean baPWV after trelagliptin administra-
tion. To the best of our knowledge, there have been no 
previous reports showing a significant improvement of 
mean baPWV as a result of DPP-4 inhibitor administra-
tion. It has been reported that in addition to improved 
blood glucose levels, baPWV decreases might be affected 
by decreases in body weight and BMI or by increases in 
adiponectin [30, 43]. In the present study, decreasing ten-
dencies, although not statistically significant, were noted 
in body weight and BMI following trelagliptin adminis-
tration, and adiponectin increased significantly. These 
changes may have resulted in the statistically significant 
decrease observed for mean baPWV after trelagliptin 
administration.
It should be noted that this study has some limita-
tions. The first potential issue is the patient character-
istics of the subjects enrolled in this study. Compared 
with previous studies that examined the effects of 
DPP-4 inhibitors administered once per day on vascular 
endothelial functions, patients in this study had a longer 
duration of DM, and thus, potentially more advanced 
arteriosclerosis. It was likely that the effects of individ-
ual vascular endothelial function and improvement of 
vascular endothelial function with treatment interven-
tion were relatively small in the patients comprised in 
this study [44, 45]. Therefore, we believe that further 
studies are necessary to examine patients with a shorter 
duration of DM. The second potential issue is fac-
tors potentially affecting vascular endothelial function, 
including antihypertensive drugs, lipid-lowering drugs, 
smoking, and caffeine intake. Although tests were per-
formed without preparing these drugs and after provid-
ing thorough lifestyle-related advice, the effects of these 
factors may not have been eliminated. The third issue is 
the likelihood of the power being too weak because of 
the small population of patients. Further studies were 
considered necessary to examine a larger population of 
patients. The fourth issue is a problem of compliance. 
HbA1c did not change despite a significant reduction in 
fasting plasma glucose (FPG). We instructed subjects to 
take medicine regularly. However, the possibility of poor 
compliance was considered. The fifth issue involves the 
nonmeasurement of GLP-1 level and DPP-4 activity 
in this study. Therefore, we cannot determine whether 
trelagliptin has various effects based on the GLP-1 level 
and DPP-4 activity. Finally, the issue is that this study 
was intended to evaluate the vascular endothelial func-
tion at baseline and after trelagliptin treatment, with a 
study design that incorporated no control group. It will 
be necessary to conduct additional studies with a design 
that incorporates control groups to further verify the 
causal relationships.
Conclusion
In this pilot study, trelagliptin treatment showed no 
significant changes in FMD. On the other hand, it was 
believed that trelagliptin treatment may increase serum 
adiponectin level. A limitation of this study is the small 
number of subjects examined and the absence of any 
control group. Therefore, we cannot apply our results to 
the general population of type 2 diabetes patients. Fur-
ther studies, in particular two- or multi-arms trial, would 
be necessary to elucidate these points.
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